Synthesis and Optimization of a New Family of Type 3 17β-Hydroxysteroid Dehydrogenase Inhibitors by Parallel Liquid-Phase Chemistry-Reference-Cited by-同舟云学术

Synthesis and Optimization of a New Family of Type 3 17β-Hydroxysteroid Dehydrogenase Inhibitors by Parallel Liquid-Phase Chemistry

Published:2001-12-27 Issue:3 Volume:45 Page:640-653
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Maltais René¹,Luu-The Van¹,Poirier Donald¹

Affiliation:

1. Medicinal Chemistry Division, Oncology and Molecular Endocrinology Research Center, Centre Hospitalier Universitaire de Québec (CHUQ) and Université Laval, 2705 Laurier Boulevard, Sainte-Foy, Québec G1V 4G2, Canada

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm010286y

Reference41 articles.

1. Testicular 17β-hydroxysteroid dehydrogenase: Molecular properties and reaction mechanism

2. Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition

3. The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology

4. Intracrinology

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemical synthesis of fluorinated and iodinated 17β-HSD3 inhibitors and evaluation for imaging prostate cancer tumors and tissue biodistribution;Bioorganic Chemistry;2022-12

2. Synthesis of 17β-hydroxysteroid dehydrogenase type 10 steroidal inhibitors: Selectivity, metabolic stability and enhanced potency;European Journal of Medicinal Chemistry;2021-01

3. Formation of Ethers by Acetal, Carbonyl, and Ortho Ester Conversions;Comprehensive Organic Transformations;2018-02-28

4. Impact of androstane A- and D-ring inversion on 17β-hydroxysteroid dehydrogenase type 3 inhibitory activity, androgenic effect and metabolic stability;Bioorganic & Medicinal Chemistry;2017-04

5. Investigation of the In Vitro and In Vivo efficiency of RM-532-105, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, in LAPC-4 prostate cancer cell and tumor models;PLOS ONE;2017-02-09